In vivo use of ivermectin (IVR) for treatment for corona virus infected patients: a randomized controlled trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000033627

Enrollment

Unknown

Registered

2020-06-07

Start date

2020-06-10

Completion date

Unknown

Last updated

2020-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

1:placebo

2:USE OF IVERMECTIN (IVR)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adults with positive PCR for COVID-19 (asymptomatic for the Pilot intervention); 2. Body weight more than 45kg; 3. Consent for voluntary participation.

Exclusion criteria

Exclusion criteria: 1. Patients with end stage heart failure; 2. Recent cardiac intervention (less than 2 months): coronary angioplasty, ICD, CABG, Valvuloplasty or replacement; 3. Pulmonary fibrosis or advanced COPD; 4. End stage kidney or liver disease; 5. Pregnant or lactating ladies; 6. Patients on immunosuppressive therapy; 7. Active tuberculosis; 8. Active hepatitis; 9. Patients requiring planned blood transfusion (Thalasemia major, aplastic anemia).

Design outcomes

Primary

Measure	Time frame
Reduction of viral load and treating COVID-19 infection;	—

Countries

Iraq

Contacts

Public ContactDr. Houssam RaaD

Beirut Arab University

raadhoussam@yahoo.fr+96 1 71026104

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 2, 2026